Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Albemarle (NYSE:ALB) has been analyzed by 17 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 2 | 6 | 8 | 1 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 1 | 0 | 0 | 1 | 0 |
2M Ago | 0 | 5 | 4 | 0 | 0 |
3M Ago | 0 | 1 | 4 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $141.29, with a high estimate of $191.00 and a low estimate of $81.00. A 10.84% drop is evident in the current average compared to the previous average price target of $158.47.
The standing of Albemarle among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Matthew DeYoe | B of A Securities | Raises | Buy | $156.00 | $137.00 |
Christopher Kapsch | Loop Capital | Lowers | Buy | $162.00 | $168.00 |
Vincent Andrews | Morgan Stanley | Lowers | Underweight | $81.00 | $90.00 |
Kevin McCarthy | Vertical Research | Announces | Hold | $145.00 | - |
John Roberts | Mizuho | Lowers | Neutral | $112.00 | $115.00 |
Aleksey Yefremov | Keybanc | Lowers | Overweight | $159.00 | $178.00 |
John Roberts | Mizuho | Raises | Neutral | $115.00 | $105.00 |
Michael Sison | Wells Fargo | Lowers | Overweight | $135.00 | $140.00 |
Arun Viswanathan | RBC Capital | Lowers | Outperform | $138.00 | $140.00 |
Colin Rusch | Oppenheimer | Lowers | Outperform | $188.00 | $191.00 |
Aleksey Yefremov | Keybanc | Lowers | Overweight | $178.00 | $199.00 |
Joshua Spector | UBS | Lowers | Neutral | $125.00 | $137.00 |
Patrick Cunningham | Citigroup | Lowers | Neutral | $120.00 | $175.00 |
Joshua Spector | UBS | Lowers | Neutral | $137.00 | $142.00 |
David Deckelbaum | TD Cowen | Announces | Market Perform | $130.00 | - |
Christopher Parkinson | Mizuho | Lowers | Neutral | $130.00 | $152.00 |
Colin Rusch | Oppenheimer | Lowers | Outperform | $191.00 | $308.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Albemarle's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Albemarle analyst ratings.
Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the U.S. and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the U.S., Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants. It is also a major producer of oil refining catalysts.
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Negative Revenue Trend: Examining Albemarle's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -10.1% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Albemarle's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -26.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Albemarle's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -6.4%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Albemarle's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -3.33%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.45, Albemarle adopts a prudent financial strategy, indicating a balanced approach to debt management.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ALB